The role of thalidomide in dermatology

被引:6
|
作者
Hussain, K. [1 ]
Patel, P. [1 ]
Roberts, N. [1 ]
机构
[1] Chelsea & Westminster Hosp NHS Fdn Trust, Dept Dermatol, London, England
关键词
NECROBIOTIC XANTHOGRANULOMA; THERAPY; LENALIDOMIDE; NEUROPATHY; PATIENT; LESIONS;
D O I
10.1111/ced.15019
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Thalidomide is a medication that has been in existence for over half a century, and has proven to be useful and effective in severe dermatological conditions. For dermatologists, the ability of thalidomide to reduce the levels of the cytokine tumour necrosis factor-alpha, along with its immunomodulatory and anti-angiogenic properties, is of great significance, with the added advantage of being an oral medication. Its use is of course strictly monitored, owing to its potential adverse effects (AEs), particularly teratogenicity, with precautions taken to ensure its safe and correct use by both prescriber and patient. In this review, we look at the background and mechanism of action of thalidomide, provide an overview of conditions it can be used for with case examples, explain the potential AEs and monitoring requirements, and discuss future developments.
引用
收藏
页码:667 / 674
页数:8
相关论文
共 50 条
  • [31] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease
    Akobeng, Anthony K.
    Stokkers, Pieter C.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (02):
  • [32] The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple MyelomaAn Overview of Clinical and Economic Information
    Andrea Messori
    Dario Maratea
    Chiara Nozzoli
    Alberto Bosi
    PharmacoEconomics, 2011, 29 : 269 - 285
  • [33] Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells
    Qiu, Xu-Hua
    Shao, Jing-Jing
    Mei, Jian-Gang
    Li, Han-Qing
    Cao, Hong-Qin
    ACTA HAEMATOLOGICA, 2016, 135 (02) : 103 - 109
  • [34] Cereblon E3 ligase complex genes are expressed in tissues sensitive to thalidomide in chicken and zebrafish embryos but are unchanged following thalidomide exposure
    Fraga, Lucas Rosa
    Reeves, Jessica
    Mahony, Chris
    Erskine, Lynda
    Vargesson, Neil
    DEVELOPMENTAL BIOLOGY, 2025, 522 : 156 - 170
  • [35] A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
    Lokhorst, Henk M.
    van der Holt, Bronno
    Zweegman, Sonja
    Vellenga, Edo
    Croockewit, Sandra
    van Oers, Marinus H.
    Borne, Peter von dem
    Wijermans, Pierre
    Schaafsma, Ron
    de Weerdt, Okke
    Wittebol, Shulamiet
    Delforge, Michel
    Berenschot, Henriette
    Bos, Gerard M.
    Jie, Kon-Siong G.
    Sinnige, Harm
    van Marwijk-Kooy, Marinus
    Joosten, Peter
    Minnema, Monique C.
    van Ammerlaan, Rianne
    Sonneveld, Pieter
    BLOOD, 2010, 115 (06) : 1113 - 1120
  • [36] Thalidomide for POEMS syndrome
    Kim, So Yeon
    Lee, Sun Ah
    Ryoo, Hun Mo
    Lee, Kyung Hee
    Hyun, Myung Soo
    Bae, Sung Hwa
    ANNALS OF HEMATOLOGY, 2006, 85 (08) : 545 - 546
  • [37] Thalidomide for necrobiotic xanthogranuloma
    Ali, F. R.
    Lear, J. T.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (04) : 769 - 770
  • [38] Thalidomide pharmacokinetics in sheep
    Smith, S. L.
    Singh, P.
    Harding, D.
    Lun, D.
    Chambers, J. P.
    NEW ZEALAND VETERINARY JOURNAL, 2016, 64 (04) : 238 - 242
  • [39] The many lives of thalidomide
    Patel, Mehul P.
    Chanan-Khan, Asher A.
    LEUKEMIA & LYMPHOMA, 2009, 50 (06) : 861 - 862
  • [40] Thalidomide neuropathy in childhood
    Fleming, FJ
    Vytopil, M
    Chaitow, J
    Jones, HR
    Darras, BT
    Ryan, MM
    NEUROMUSCULAR DISORDERS, 2005, 15 (02) : 172 - 176